COVID-19 pneumonia manifests among others with a thick bronhial secretion. It contains an
increased number of neutrophil extracellular traps (NETs), formed during netosis. DNA is a
major component in NETs. DNAse alfa (Pulmozyme®, Roche) is a recombinant human enzyme,
registered for inhalations in patients with Cystic fibrosis, in which NETs are also a typical
characteristic. DNAse alfa inhalations are typically well tolerated and with no major side
effects. Some initial reports exist of using DNAse alfa inhalations in COVID-19 patients,
that had benefitial effects. There are some trials registered with ClinicalTrials,
investigating the usufulness of DNAse alfa in intubated patients, but the investigators have
no knowledge of a trial, investigating the usufulness of this drug in patients receiving High
Flow Nasal Oxygen therapy.